Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10261867 | 0.87 | HRH3 (0.40) | GPR119CHEK2MCHR1HRH3 | |
| SCHEMBL1376147 | 0.81 | HRH3 (0.62) | HRH3 | |
| SCHEMBL1374170 | 0.80 | HRH3 (0.43) | GPR119CHEK2HRH3 | |
| Trifluoroacetic Acid SCHEMBL1373010 | 0.79 | GRK6 (0.40) | CHEK2HRH3 | |
| SCHEMBL1375909 | 0.73 | HRH3 (0.64) | GPR119CHEK2HTTHRH3 | |
| SCHEMBL1376313 | 0.72 | GSK3A (0.50) | HTT | |
| SCHEMBL3616190 | 0.72 | HRH3 (0.52) | GPR119CHEK2HTTHRH3 | |
| SCHEMBL2735422 | 0.72 | GPR119 (0.67) | GPR119CHEK2NPBWR1MCHR1HRH3 | |
| SCHEMBL21825088 | 0.72 | HDAC4 (0.70) | GPR119CHEK2 | |
| SCHEMBL3613207 | 0.71 | HRH3 (0.61) | GPR119CHEK2HTTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069312-B1 | PYRIDIZINONE DERIVATIVES | CEPHALON INC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2069312-A2 | PYRIDIZINONE DERIVATIVES | Cephalon, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | GPR119 1540/4885CHEK2 679/4885HTT 2215/4885 |
| US-20100280007-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | GPR119 660/4885CHEK2 2099/4885HTT 284/4885 |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | GPR119 611/4885CHEK2 2223/4885HTT 226/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | GPR119 660/4885CHEK2 2099/4885HTT 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.